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Advance Access published on July 25, 2013Atopic dermatitis (AD) is the most common dermatological disease of childhood. Many children with AD have
asthma and AD shares regions of genetic linkage with psoriasis, another chronic inﬂammatory skin disease.
We present here a genome-wide association study (GWAS) of childhood-onset AD in 1563 European cases
with known asthma status and 4054 European controls. Using Illumina genotyping followed by imputation,
we generated 268034 consensus genotypes and in excess of 2 million single nucleotide polymorphisms
(SNPs) for analysis. Association signals were assessed for replication in a second panel of 2286 European
casesand3160Europeancontrols.Fourlociachievedgenome-widesigniﬁcanceforADandreplicatedconsist-
entlyacrossallcohorts.Theseincludedtheepidermaldifferentiationcomplex(EDC)onchromosome1,thegen-
omic region proximal to LRRC32 on chromosome 11, the RAD50/IL13 locus on chromosome 5 and the major
histocompatibility complex (MHC) on chromosome 6; reﬂecting action of classical HLA alleles. We observed
variation in the contribution towards co-morbid asthma for these regions of association. We further explored
the genetic relationship between AD, asthma and psoriasis by examining previously identiﬁed susceptibility
SNPsforthesediseases.WefoundconsiderableoverlapbetweenADandpsoriasistogetherwithvariablecoin-
cidencebetweenallergicrhinitis(AR)andasthma.OurresultsindicatethatthepathogenesisofADincorporates
immune and epidermal barrier defects with combinations of speciﬁc and overlapping effects at individual loci.
INTRODUCTION
Atopicdermatitis(AD)isachronicrelapsinginﬂammatoryskin
disease that may affect 20% of children and 3% of adults. Up to
60%ofchildrenwithsevereADwilldevelopasthma(1),andin-
fantile AD is a strong predictor of subsequent asthma develop-
ment (2). These observations are consistent with the genetic
correlationof0.35–0.55(3,4)foundbetweenthesetwostrongly
heritable(5–10)diseases,andindicatessomesharedelementsof
aetiology.
Despite this apparent overlap, few genes implicated in AD
have been conﬁrmed to play a role in asthma. The positionally
cloned (11,12) and highly replicated (13) FLG locus may con-
tribute towards the pathogenesis of asthma, but only within the
context of AD (11,14). FLG mutations have not been found to
be a risk factor for asthma alone, suggesting that ‘AD plus
asthma’ is a genetically distinct form of asthma or a speciﬁc
endophenotype of AD (11,14,15). In contrast, far greater levels
of genomic coincidence have been observed between AD and
psoriasis (1), another common familial inﬂammatory skin
disease. While not mutually exclusive, AD and psoriasis rarely
co-exist. They share a number of similar features, particularly
in the chronic phase of AD, including epidermal hyperplasia
and altered terminal differentiation of keratinocytes (16,17), as
well as a number of highly divergent features, such as the level
of corniﬁcation and susceptibility towards recurrent bacterial,
viral or fungal infections.
Genome-wide association studies (GWAS) have conﬁrmed
theassociationbetweenADandtheFLGlocus(18–21)andspe-
ciﬁed additional contributory loci at 2q12 (21), 3p21.33 (21),
3q13.2 (21), 5q22.1 (19,21), 5q31.1 (18,21), 6p21.3 (21), 7p22
(21), 10q21.2 (21), 11p15.4 (21), 11q13.1 (18,21), 11q13.5
(18,20,21), 19p13.2 (18,21) and 20q13 (18,19,21). To date,
morethanhalfoftheselocihaveonlybeenobservedinJapanese
populations. As yet, none of these GWAS have speciﬁcally
examined the differing genetic contribution of individual loci
to the AD endophenotypes ‘AD plus asthma’ and ‘AD no
asthma’ on a genome-wide scale.
Inthisstudy,weconsequentlyhavesetouttomapthegenetic
architecture of AD in a Northern European population and to
explore the genetic overlap between AD and asthma in the
same dataset (Fig. 1). Using existing evidence from GWAS of
psoriasis, we also sought to identify genetic communalities
between these two common inﬂammatory skin diseases.
RESULTS
Thediscoveryphasecomprised1563childhoodonsetmoderate-
severe ADcases ofEuropean descent recruited through second-
ary and tertiary referral centres and 4054 population controls of
matched ancestry. The subject set incorporated independent
cohorts from the UK and Ireland (881 cases, 3442 controls)
and Germany (682 cases, 612 controls). Overall, 36.4% of the
cases also had a doctor diagnosis of asthma (Table 1; Supple-
mentary Material, Table S1). A total of 268 034 observed and
2406 139 imputed single nucleotide polymorphisms (SNPs)
passed quality control ﬁlters. There was little evidence of inﬂa-
tion of the test statistic due to population stratiﬁcation, but a
marked enrichment for signiﬁcant values at the tail of the distri-
bution. Genomic control (GC) inﬂation factors for the UK and
German portions of the cohort with 10 principal components
as covariates were 0.995 and 1.010, respectively, for AD,
1.007 and 1.005 for AD and asthma, and 0.977 and 0.997 for
AD not asthma. For the data with GC factor ≤1.00, no further
adjustments were made. For the data with GC factor .1.00,
genomic control was applied prior to meta-analysis.
Contiguous regions of association to AD (irrespective of
asthma status) were observed on chromosomes 1q21 (top SNP
rs11205006, P ¼ 1.02E215), 2q22 (top SNP rs1469621,
P ¼ 3.88E209), 5q31 (top SNP rs2158177, P ¼ 2.65E210),
6p21 (top SNP rs6474, P ¼ 1.61E209) and 11q13 (top SNP
rs2155219,P ¼ 8.17E209)(Fig.2).Thelinkagedisequilibrium
(LD)patternsacrosstheregionswereconsistentwithsingleeffect
loci on chromosomes 2q22 and 11q13, and multi-effect loci
on chromosomes 1q21, 5q31 and 6p21 (Fig. 3). Independence
among association signals at each of these sites was tested expli-
citlyviathreecyclesofconditionallogisticregression,sequential-
ly incorporating the strongest associations as covariates.In order
to increase the minimum observed P-value .0.0001, it was
4842 Human Molecular Genetics, 2013, Vol. 22, No. 23necessary to condition on three markers on chromosome 1q21
(rs11205006, rs12086263 and rs17670505), two markers on
chromosome 5q31 (rs2158177 and rs157573) and 6p21 (rs6474
and rs3134929), and one marker on chromosome 2q22
(rs1469621) and 11q13 (rs2155219).
The association signal on chromosome 1 coincided with the
FLG locus (13), the most robust known genetic risk factor for
AD (22), and one of the strongest known genotype–phenotype
associations of any complex trait. Independence among the
chromosome 1 SNPs and the most common FLG AD risk
alleles(R501Xand2282del4)wasassessedbylogisticregression
(SupplementaryMaterial,TableS2).KnownFLGADriskalleles
accountedforthemajorityofvarianceobservedatthissitewithno
signiﬁcant residual effects attributable to other associated SNPs.
The association at this site was more pronounced in individuals
with both AD and asthma, as compared with those with AD
alone(Fig.2).Thisobservationisconsistentwithdata,suggesting
that the risk for asthma conferred by FLG variants is limited to
asthma occurring within the context of AD (23,24).
InclusionofasthmadiseasestatusintotheGWASmodel(AD
plus asthma, AD no asthma) did not lead to the identiﬁcation of
any additional loci signiﬁcant at a genome-wide threshold (P ≤
5.0E208, Fig. 2). All 5 loci achieved peak signiﬁcance when
asthma status was not taken into account in the model most
likely reﬂecting increased power through increased case
numbers. Nevertheless, considerable variability was observed
between loci; with the loci on chromosomes 1 and 5 achieving
markedly greater signiﬁcance in the ‘AD plus asthma’ group
compared with the ‘AD no asthma’ group. The reverse scenario
was observed for chromosome 6 (Fig. 2).
Figure 1. Schemata of study design.
Table 1. Sample and population summary
Variable European ancestry discovery sets European ancestry replication sets
UK and Irish German Total Irish and
Scottish
German Swedish Total
n (cases/controls) 881/3442 682/612 1563/4054 631/996 1241/1178 414/986 2286/3160
Mean age (cases/controls) 7.2 (8.8)/
39.2 (13.5)
25.2 (14.1)/
9.6 (0.7)
15.0 (14.5)/
34.7 (16.4)
2.8 (3.6)/
38.3 (12.7)
21.4 (16.6)/
26.7 (17.3)
29.2 (13.9)/
8.3 (0.49)
19.0 (16.8)/
24.5 (17.6)
% Male cases 57.7 39.1 49.6 59.5 45.7 40.3 47.8
% Male controls 51.2 49.3 51.0 57.8 43.9 50.9 50.4
% Asthma
a 37.0 35.6 36.4 15.0 31.8 45.4 29.9
Genotyping Illumina 300 K/610K Illumina 300K – TaqMan Sequenom Sequenom and
TaqMan
–
aBased on the individuals with data available.
Human Molecular Genetics, 2013, Vol. 22, No. 23 4843We sought replication of our ﬁndings by selecting the
highest ranking SNPs with a consistent direction of effect in
UK–Irish and German cohorts from the GWA discovery stage
(P , 1.0E205). Multiple SNPs ranked high from a single
chromosomal region were ﬁltered to exclude those in LD
(r
2 . 0.3) with the highest ranking SNP. Potentially functional
Figure2.ManhattanplotofGWASresults.ManhattanplotsrelatingtoeachstrataoftheGWAanalysispresentedinthefollowingorder:AD(all),ADandasthma,AD
noasthma.Thethresholdforgenome-widesigniﬁcance(P ≤ 5.0E208)isshownoneachplotasasolidredline.Asuggestivethresholdof1.0E205isshownasasolid
blue line. Abbreviations: 2log10(P-value), the base 10 logarithm of the probability (P) values; AD, atopic dermatitis.
4844 Human Molecular Genetics, 2013, Vol. 22, No. 23SNPs from LD bins were retained. SNPs from the known FLG
locus on chromosome 1 were not included due to prior replica-
tion by others. A total of 47 SNPs (Supplementary Material,
Table S3) were carried forward to the replication cohorts,
which contained 2286 cases and 3160 controls derived from
Ireland, Scotland, Sweden and Germany.
Figure3. Detailed maps of regions showing robust evidenceof association, includingsites which replicatesuccessfully across all cohorts,and the established 1q21
locus.PointsarecolouredaccordingtotheextentofLD(asmeasuredbytheirr
2values)asindicatedbythecolourscale.Thepresenceofassociationpeakswithadark
bluecolourindicatesindependentassociation.TheshapeofindividualpointsreﬂectstheUniSNPdatabaseannotation(seelegendandhttp://research.nhgri.nih.gov/
tools/unisnp/?Rm=ohelp). Mb, megabase; Chr, chromosome; nonsyn, nonsynonamous; utr, untranslated region; tfbscon, conserved, predicted transcription factor
binding side; mcs44placental, conserved, placental mammals. (A) Chromosome 1q21. (B) Chromosome 5q31. (C) Chromosome 6p21. (D) Chromosome 11q13.
Table 2. Association results of the GWAS screen and replication studies for AD
SNP Chr Pos A1 A2 Gene Screen
a Replication
b Combined
c
OR P OR P OR P
rs2897443 5 131957493 T G RAD50 1.350 (1.196–1.525) 1.27E206 1.284 (1.171–1.408) 1.20E207 1.308 (1.215–1.407) 8.95E213
rs6871536 5 131997773 T C RAD50 0.738 (0.655–0.832) 7.27E207 0.747 (0.678–0.822) 3.42E209 0.743 (0.69–0.799) 2.11E215
rs2158177 5 132011957 A G RAD50/IL13 0.611 (0.524–0.712) 2.65E210 0.738 (0.672–0.811) 2.49E210 0.704 (0.634–0.782) 5.90E211
rs1295686 5 132023742 T C IL13 1.420 (1.255–1.606) 2.66E208 1.362 (1.24–1.496) 9.80E211 1.383 (1.283–1.49) 1.65E217
rs20541 5 132023863 A G IL13 1.426 (1.260–1.613) 1.79E208 1.365 (1.202–1.55) 1.56E206 1.39 (1.278–1.512) 1.93E214
rs2251396 6 31472686 A G HLA-B 1.325 (1.178–1.490) 2.65E206 1.23 (1.109–1.365) 1.09E204 1.267 (1.174–1.368) 1.28E209
rs2844509 6 31618903 A G BAT1 1.345 (1.184–1.529) 5.64E206 1.624 (1.249–2.112) 3.00E204 1.312 (1.215–1.417) 4.33E212
rs9368699 6 31910520 T C C6orf48 1.894 (1.432–2.505) 7.61E206 1.531 (1.201–1.952) 5.81E204 1.677 (1.396–2.014) 3.19E208
rs12198173 6 32134786 A G TNXB 0.649 (0.539–0.782) 5.56E206 0.676 (0.571–0.801) 5.32E206 0.664 (0.586–0.752) 1.33E210
rs12211410 6 32157401 T C TNXB 0.651 (0.540–0.784) 6.35E206 0.719 (0.619–0.834) 1.56E205 0.692 (0.615–0.777) 5.78E210
rs13199524 6 32174743 T C TNXB 0.639 (0.528–0.773) 3.81E206 0.63 (0.514–0.772) 8.96E206 0.641 (0.564–0.728) 8.01E212
rs12153855 6 32182782 T C CREBL1 1.541 (1.296–1.832) 9.46E207 1.665 (1.353–2.05) 1.46E206 1.581 (1.405–1.779) 2.96E214
rs7130588 11 75948331 A G C11orf30 0.770 (0.694–0.853) 5.81E207 0.794 (0.708–0.889) 7.44E205 0.778 (0.727–0.833) 4.49E213
rs2155219 11 75976842 T G C11orf30/
LRRC32
1.360 (1.225–1.510) 8.17E209 1.319 (1.205–1.444) 1.66E209 1.323 (1.224–1.429) 1.61E212
Genome build hg18, dbSNP130. The Filaggrin (FLG) locus is not included in the table as replication was not sought.
aMeta-analysis of German and UK screening cohorts.
bMeta-analysis of replication samples using a random-effects model.
cMeta-analysis of the screen and the three replication cohorts using a random-effects model.
Human Molecular Genetics, 2013, Vol. 22, No. 23 4845Sixteen SNPs from three different genomic regions showed
evidence of replication after Bonferroni correction for the 47
tests (P , 0.001). Associations were with the same allele and
in the same direction as the discovery phase. Fourteen of the
16 SNPs achieved genome-wide signiﬁcance inameta-analysis
incorporating all study collections (P , 5.0E208, Table 2).
These SNPs were positioned on chromosomes 5q31 (5 SNPs),
6p21 (7 SNPs) and 11q13 (2 SNPs).
Chromosome 6p21—the MHC locus
We identiﬁed a strong signal in the major histocompatibility
complex (MHC) region on chromosome 6 with a number of
weakly correlated (r
2 , 0.4) markers reaching genome-wide
signiﬁcance. Nine of the 24 SNPs achieved signiﬁcance in a
meta-analysis of the replication cohorts following a correction
for multiple testing. Of these, seven SNPs achieved a P-value
of ,5.0E208 when tested for association in the combined
discovery and replication datasets. A peak association P-value
of 2.96E214 was achieved at marker rs12153855 in the class
III region of the MHC. This SNP was intronic to the gene
Tenascin XB (TNXB; a gene previously implicated in systemic
lupus erythematosus (25)), and positioned just 83 kb from the
previously published peak of association for AD within the
MHC(rs176095)(26).Rs176095achievednominalsigniﬁcance
in our dataset (Table 4, P ¼ 0.0031). Independence among
these signals was assessed by conditional regression. When
conditioned on rs176095, the effect of rs12153855 was wea-
kened, but not eliminated (b ¼ 0.3741, SE ¼ 0.0980 and
P ¼ 0.0001354).
TheMHCischaracterizedbyhighlevelsofduplication,poly-
morphism and LD. We applied two strategies in order toextract
maximal information from the observed association.
First, we used existing expression quantitative trait locus
(eQTL) data derived from 496 subjects from the UK portion of
thediscoverycohort(27)inordertosearchforeQTLcoincident
withthesevenreplicatedSNPs.Thesedataweregeneratedusing
RNA prepared from Epstein-Barr virus (EBV)–transformed
lymphoblastoid cell lines followed by expression analysis with
Illumina Human 6 BeadChips (27). The proximal genomic
region (31–33 Mb) encapsulating the seven replicated SNPs
wasexaminedforcis-ortrans-actingeQTLcapableofaffecting
any transcript represented on the Illumina 6 Human BeadChip
(including .33 000 RefSeq transcripts). The seven SNPs of
interest were not found to align with the most signiﬁcant eQTL
intheregion,althougheffectsinothercelltypesorphysiological
conditionscannotbeexcluded.TheSNPsneverthelessdidshow
moderatelevelsofassociationwithanumberofgeneexpression
traits(Fig.4).Themostsigniﬁcanthitswerethenaturalcytotox-
icity triggering receptor NCR3 (rs2844509, LOD ¼ 14.7),
ATPase ATP6V1G2 (rs2844509,LOD ¼ 10.5), activating tran-
scription factor CREBL1 (four SNPs, LOD range ¼ 9.2–8.6),
and HLA-DRB5 (ﬁve SNPs, LOD range ¼ 9.1–3.5).
We next imputed classical HLA alleles using the dense SNP
genotype data of the discovery phase subject set, using a pub-
lished statistical methodology previously shown to impute
HLA alleles from SNP data with 92–98% accuracy at the four-
digit level. (28–30). Signiﬁcant associations were observed for
HLA-B∗5701 (P ¼ 6.08E205), B∗4402 (P ¼ 9.60E205),
DRB1∗0701 (P ¼ 1.36E207), DRB1∗0401 (P ¼ 7.62E204),
DRB1∗1101 (P ¼ 1.35E203), DQA1∗0201 (P ¼ 6.03E206),
DQA1∗0301 (P ¼ 1.26E203), DQB1∗0301 (P ¼ 3.82E205)
and DQB1∗0202 (P ¼ 1.44E204). Taking the most signiﬁcant
association, HLA-DRB1∗0701 (protective for AD OR ¼ 0.65)
and using conditional analysis, we tested for independence of
the association from the other HLA loci. Only a marginal asso-
ciation of HLA-B∗4402 remained (P ¼ 0.0015). When condi-
tioning on both HLA-DRB1∗0701 and HLA-B∗4402, none of
the other loci were signiﬁcant (P , 0.01) after correction for
multiple testing. These results indicate that the association
signal observed within the margins of the MHC may reﬂect the
action of classical HLA alleles with typed markers acting as
proxies. In particular, our data suggest that HLA-DRB1∗0701
confers a signiﬁcant protective effect on AD, and that
HLA-B∗4402 slightly increases the risk of AD independent of
DRB1∗0701 (Table 3).
PolymorphismsintheDRbetachainsoftheClassIIHLAmol-
ecule specify peptide-binding afﬁnities. The HLA-DRB1∗0701
allele found here to associate with AD has previously been asso-
ciated with a range of T-cell mediated inﬂammatory diseases
Figure 4. eQTL analysis of the chromosome 6 locus. Transcript abundance associations signiﬁcant at a 1% false discovery rate. Individual single nucleotide
polymorphism (SNP)–transcript associations with a LOD (Logarithmof the Odds) scoreof .10 are labelled. SNPs are colouredaccording to theirassociated tran-
scripts. SNPs found to be signiﬁcantly associated with AD in the discovery and replication cohorts are shown as triangles. All other SNPs are shown as circles.
4846 Human Molecular Genetics, 2013, Vol. 22, No. 23includingpodoconiosis(31)(aninﬂammatorydiseaseofthelower
legs that occurs after long-term skin exposure to mineral micro-
particles),psoriasis(32–34)andvitiligo(35).Ineachofthesedis-
orders, the HLA-DRB1∗0701 allele increases the disease risk,
suggesting that it may have particular relevance in response to
cutaneously exposed antigens.
Wefound thatthe locus didnothave aneffect on theAD plus
asthma phenotype. Of the 24 SNPs that attained a P-value
of ,1.0E205 for AD in the discovery phase, 11 achieved
P-values below this threshold when the case status was limited
to individuals without asthma compared with only two SNPs
in cases with asthma (Supplementary Material, Table S1). In
addition, the signal reported here did not coincide with that
identiﬁed in a large-scale GWAS of asthma (36), where the
asthma association was positioned in the HLA-DQ region
(rs9273349), and showed low levels of correlation (r
2 , 0.2)
with the markers found to associate with AD in this dataset.
Chromosome 5q13
Weidentiﬁedasecondmajorsiteofassociationonchromosome
5q31. Eight SNPs in this region achieved P , 1.0E205 for AD
in the discovery phase. In contrast with the MHC, half of these
markers (four out of eight) had P-values below this threshold
when the case status was limited to the ‘AD plus asthma’ sub-
group, whereas only one SNP retained signiﬁcance in the ‘AD
no asthma’ subgroup (Supplementary Material, Table S3).
These data suggest that the chromosome 5 locus may exert
overlapping effects, affecting both AD and asthma. Consistent
with these observations, markers in this region (spanning
between the RAD50 locus to the IL13 locus) have previously
been implicated in the aetiology of asthma by GWA (36). They
have also shown genome-wide association with the intermediate
phenotypes of serum IgE and eosinophil numbers (37,38).
FiveoutofeightdiscoveryphaseSNPsretainedsigniﬁcancein
the replication data following correction for multiple testing.
AllﬁveSNPsachievedaP-valueof ,5.0E208inthecombined
discovery and replication datasets (with a peak association
P-value of 1.65E217 at rs1295686). Two distinct, but incom-
pletely independent, association signals were observed with one
block containing three of the SNPs rs2897433, rs6871536,
rs2158177 and the other block containing rs1295686 and
rs20541 (LD, r
2 . 0.89 within the two blocks, HapMap III,
release 2 CEU + TSI), suggesting that there may be more than
one susceptibility locus within the region.
One of the most strongly associated SNPs (rs20541) was a
missense variant in the gene encoding Interleukin 13 (IL13 +
2044G . A); a cytokine predominantly secreted by Th2 cells
and an important factor in the regulation of allergic inﬂamma-
tion. This variant has been repeatedly associated with asthma
as well as being shown to result in a distinct isoform of IL-13
with increased biological activity (39).
A previous GWAS of AD has identiﬁed a peak marker
(rs2897442) located in an intron of KIF3A in the 5q31
genomic region (18) This signal is located .50 kb away from
the site of association reported here, yielded P-values of lower
signiﬁcance (Table 4), and demonstrates only minimal levels
of LD (r
2 , 0.1, D’ , 0.4 based on the CEU 1000 Genomes
dataset) with the ﬁve replicated SNPs inthiscurrent study.Sub-
sequent high-resolution mapping of the region, however,
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Human Molecular Genetics, 2013, Vol. 22, No. 23 4847Table 4. Association with published GWA markers for AD
Reference Marker Risk
allele
Gene Allele 1 Allele 2 AD all AD and asthma AD not asthma
Effect StdErr P Direction OR Effect StdErr P Effect StdErr P
Palmer et al.( 11) FLG R501X T FLG CT21.409 0.236 2.38E209 22 0.244 21.505 0.260 7.21E209 22 21.195 0.272 1.09E205 22
Palmer et al.( 11) FLG
2282del4
DEL FLG DEL 21.720 0.209 1.88E216 22 0.179 21.725 0.237 2.96E213 22 21.673 0.242 4.72E212 22
Esparza-Gordillo
et al.( 20)
rs6661961 A FLG T C 0.338 0.052 8.67E211 ++ 1.402 0.386 0.072 6.87E208 ++ 0.290 0.063 5.03E206 ++
Esparza-Gordillo
et al.( 20)
rs877776 C HRNR near FLG CG20.078 0.076 3.06E201 2+ 0.925 20.216 0.110 5.00E202 22 20.008 0.092 9.28E201 2+
Esparza-Gordillo
et al.( 20)
rs7927894 A c11orf30 T C 0.262 0.055 1.73E206 ++ 1.300 0.279 0.075 2.10E204 ++ 0.261 0.067 9.80E205 ++
Sun et al.( 19) rs3126085 A FLG AG20.060 0.079 4.46E201 2+ 0.941 20.220 0.116 5.65E202 22 0.016 0.095 8.67E201 2+
Sun et al.( 19) rs7701890 G TMEM232-SLC25A46 AG20.210 0.097 3.06E202 22 0.810 20.196 0.130 1.33E201 2+ 20.221 0.120 6.65E202 22
Sun et al.( 19) rs6010620 G TNFRSF6B-ZGPAT AG20.206 0.063 1.18E203 2+ 0.814 20.248 0.090 5.58E203 22 20.177 0.077 2.10E202 2+
EAGLE (18) rs9050 TCHH near FLG A C 0.532 0.085 3.91E210 ++ 1.703 0.567 0.112 4.30E207 ++ 0.478 0.104 4.00E206 ++
EAGLE (18) rs479844 G OVOL1 AG20.220 0.052 2.77E205 22 0.803 20.239 0.073 1.13E203 22 20.187 0.064 3.73E203 22
EAGLE (18) rs2164983 A ACTL9 A C 0.104 0.073 1.53E201 ++ 1.110 0.126 0.100 2.06E201 ++ 0.116 0.090 1.96E201 ++
EAGLE (18) rs2897442 C KIF3A TC20.218 0.057 1.18E204 22 0.804 20.250 0.078 1.33E203 22 20.193 0.070 5.97E203 22
Hirota et al.( 21) rs13015714 G IL1RL1-IL18R1-IL18RAP TG20.116 0.060 5.29E202 22 0.887 20.089 0.082 2.83E201 22 20.126 0.073 8.34E202 2+
Hirota et al.( 21) rs176095 A GPSM3 (MHC region) A G 0.211 0.071 3.13E203 ++ 1.234 0.115 0.097 2.37E201 2+ 0.311 0.089 4.63E204 ++
Hirota et al.( 21) rs878860 C OR10A3-NLRP10 T C 0.038 0.052 4.67E201 ++ 1.041 20.019 0.073 7.95E201 2+ 0.085 0.063 1.78E201 ++
Hirota et al.( 21) rs6780220 C GLB1 AC20.157 0.072 2.98E202 22 0.852 20.162 0.100 1.05E201 22 20.165 0.088 6.22E202 22
Hirota et al.( 21) rs12634229 C CCDC80 TC20.057 0.136 6.73E201 22 0.942 20.032 0.188 8.64E201 2+ 20.076 0.168 6.52E201 22
Hirota et al.( 21) rs4722404 C CARD11 TC20.074 0.055 1.84E201 22 0.932 20.112 0.077 1.47E201 22 20.048 0.067 4.78E201 2+
Hirota et al.( 21) rs10995251 C ZNF365 TC20.023 0.054 6.68E201 2+ 0.980 20.121 0.075 1.08E201 22 0.041 0.067 5.40E201 2+
Hirota et al.( 21) rs16999165 A CYP24A1-PFDN4 AG20.167 0.142 2.38E201 22 0.844 0.004 0.206 9.84E201 2+ 20.309 0.169 6.76E202 22
Hirota study is for Asian (Japanese) samples.
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3revealed a second independent signal (rs848), in only weak LD
withrs2897442,positionedinIL13andshowingstrongLDwith
the functional IL13 variant found to be associated here
(rs20541). These results are consistent with the data that we
present here, indicating that more than one effect may reside
within this region.
Chromosome 11q13.5
We mapped a third genome-wide signiﬁcant signal to an inter-
genic interval on chromosome 11q13.5 between the uncharac-
terized protein coding gene C11orf30 and the gene encoding
the leucine-rich type I membrane protein, LRRC32.This region
has previously been associated with AD (20). Two markers at
this site (rs7130588 and rs2155219) demonstrated strong and
consistent patterns of association with AD in the discovery and
replication panels (Table 2). P-values did not appear to differ
systematically between the ‘AD plus asthma’ and the ‘AD no
asthma’ strata of the analysis. Examination of the HapMap
CEU and TSI datasets revealed high levels of LD between
marker rs7130588 and the rs7927894 SNP previously shown
to be associated with AD (20)( r
2 ¼ 0.91, HapMap III, release
2), indicating that these SNPs are likely to represent a single
risk locus.
Analysisofpreviouslyidentiﬁedriskallelesforatopicdisease
and psoriasis
A composite list of variants associated with atopic diseases
[asthma,AD and allergic rhinitis (AR)], and the chronic inﬂam-
matory skin disease psoriasis, by means of GWAS, was com-
piled from the catalogue of Published GWAS (40) and
associated reference lists. Where possible, we examined these
variants for association with AD in our discovery dataset,
either directly or by imputation.
Consistent with historical evidence of genomic correspond-
ence(1),13variantspreviouslyshowntoassociatewithpsoriasis
by GWAS achieved low P-values in our dataset (Table 5). Ap-
proximately two-thirds of these variants showed opposite risk
proﬁlesforADversuspsoriasis.Theremainingone-thirdexhib-
ited an association with the same allele. These patterns may
reﬂect genetic contributions towards the divergent and shared
features of these two common dermatological diseases. A pro-
pensity towards opposing risk proﬁles is consistent with the in-
frequency of the two diseases’ co-occurrence (41).
TwoSNPsattainedsigniﬁcanceatagenome-widelevel.Both
exhibited opposing effects in AD and psoriasis, and localized
to the gene IL13 (rs1295685, P ¼ 4.94E209 and rs20541,
P ¼ 1.786E208). IL13 is an immunoregulatory cytokine pri-
marilysecretedbyactivatedThelpertypeII(Th2)cells,trigger-
ingBlymphocytestoswitchtowardsIgEproduction.Aninverse
association at this site may therefore contribute towards the
distinct immune proﬁles of psoriasis and AD (type I and type
II, respectively). Similarly, suggestive opposing signals were
also seen at several markers positioned in and around the cyto-
kine interleukin 12B (IL12B), a key cytokine in Th1 lineage
development and survival (42–44). AD and psoriasis also
differ in their susceptibility towards cutaneous bacterial and
viral infection (41). Consistent with this, suggestive opposing
signals were seen at a single marker proximal to interleukin 28
receptor alpha (interferon, lambda receptor, IL28RA); a gene
previously implicated in viral infection and resolution (45),
andatamissensemutationinTRAF3IP2;anevolutionarilycon-
served component of the host antiviral signalling pathway (46).
FourvariantsshowedequivalentriskproﬁlesinADandpsor-
iasis, such that both diseases associated with the same alleles.
These included a common, damaging missense variant (47,48)
in the gene CARD14. CARD14 is predominantly expressed in
the skin, where it activates the NF-kB pathway augmenting the
keratinocyte response to inﬂammatory cytokines.
A single variant located in the c11orf30-LRRC2 region has
previously been shown to associate with AR by GWAS
(rs2155219)(49).Thisvariantyieldedgenome-widesigniﬁcant
evidenceofassociationwithADinourdiscoveryphase(ADP ¼
8.17E209, OR 1.36); an effect of equivalent direction to that
previously reported in AR, and of similar signiﬁcance in AD
patients with (P ¼ 3.67E206) and without (P ¼ 6.01E206)
asthma (Table 6).
Wealsotestedinourdataset21variantspreviouslyimplicated
intheaetiologyofasthmabyGWA.Whilenoneoftheseachieved
criteria for genome-wide signiﬁcance, suggestive signals were
observed on chromosome 11 around the c11orf30-LRRC2 locus
described above for its role in AR (AD P ¼ 5.81E207,
rs7130588). The effect at this site matched the direction of that
reported for asthma, suggesting that this region may harbour
mechanisms capable of moderating multiple atopic disease
processes.
Lower magnitude signals were observed at a number of other
positions, including the chromosome 17 GSDMB-ORMDL3-
GSDMA locus, SMAD3, the interleukin 6 receptor (IL6R),
FLJ44477-USP38 and SUOX-IKZF4 (Table 7). These all
demonstrated a common pattern of association, achieving the
most signiﬁcant P-values in ‘AD plus asthma’ cases and
showing a complete absence of association in ‘AD no asthma’
cases. This implies that association at these sites may be
primarily driven by asthma status.
DISCUSSION
We have presented here a GWAS of AD in a large panel of
Northern European cases with childhood onset disease and
known asthma status. We identiﬁed loci involved in the aeti-
ologyofADatthewell-establishedFLGlocusonchromosome1,
the MHC on chromosome 6p21, the RAD50/IL13 locus on
chromosome5q31andan11q13.5locusinstrongLDwithapre-
viously characterized AD susceptibility site (20). We show that
variation exists between these loci interms of their contribution
towards co-morbid asthma, and furthermore, that genomic
overlap between AD and psoriasis can be explained by a
pattern of systematic association with the same markers, but
not necessarily the same alleles.
The MHC has only previously been implicated in AD in a
single cohort of Japanese origin (21). Here, we observe an inde-
pendentassociationsignalincloseproximitywiththatprevious-
ly reported. The associated variants did not exhibit pronounced
directeffectsongeneexpressioninthecelltypestudied,indicat-
ing an alternative mode of action, indirect association or tissue-
speciﬁc effects. By imputation, we are able to show that this
signal, identiﬁed here in a Caucasian population of Northern
Human Molecular Genetics, 2013, Vol. 22, No. 23 4849Table 5. Association with published GWA markers for psoriasis
Reference SNP Risk allele Gene Allele 1 Allele 2 Effect StdErr P OR Direction
Tsoi et al. (47) rs11121129 A SLC45A1,TNFRSF9 A G 0.1275 0.0561 2.30E202 1.14 Same
Tsoi et al. (47) rs7552167 G IL28RA A G 0.1531 0.0732 3.65E202 1.17 Opposite
Tsoi et al. (47) rs7536201 C RUNX3 A G 0.0769 0.0559 1.69E201 1.08
Nair et al. (73) rs2201841 G IL23R A G 20.0216 0.0556 6.98E201 0.98
Tsoi et al. (47) rs9988642 T IL23R T C 0.0783 0.0621 2.07E201 1.08
Zhang et al. (74) rs4085613 ? LCE3D T G 0.0048 0.0546 9.30E201 1.00
WTCCC2 (75) rs4112788 ? LCE3D A G 0.0041 0.0539 9.40E201 1.00
Tsoi et al. (47) rs6677595 T LCE3B,LCE3D T C 20.0037 0.0539 9.45E201 1.00
WTCCC2 (75) rs702873 G REL T C 20.0890 0.0522 8.85E202 0.91
Tsoi et al. (47) rs62149416 T FLJ16341,REL A C 20.0464 0.0523 3.75E201 0.95
Tsoi et al. (47) rs10865331 A B3GNT2 A G 20.0434 0.0528 4.11E201 0.96
WTCCC2 (75) rs17716942 A IFIH1 T C 20.0334 0.0852 6.95E201 0.97
Tsoi et al. (47) rs17716942 T KCNH7,IFIH1 T C 20.0334 0.0852 6.95E201 0.97
WTCCC2 (75) rs27524 A ERAP1 A G 20.0230 0.0532 6.66E201 0.98
Tsoi et al. (47) rs27432 A ERAP1 A G 0.0002 0.0574 9.97E201 1.00
Nair et al. (73) rs20541 G IL13 A G 0.3547 0.0630 1.79E208 1.43 Opposite
Tsoi et al. (47) rs1295685 G IL13,IL4 A G 0.3782 0.0647 4.94E209 1.46 Opposite
Tsoi et al. (47) rs2233278
a C TNIP1 T C 20.0057 0.1027 9.55E201 0.99
Nair et al. (73) rs17728338 A TNIP1 A G 20.1376 0.1221 2.60E201 0.87
Nair et al. (73) rs2082412 G IL12B A G 0.1481 0.0639 2.05E202 1.16 Opposite
Cargill et al. (76) rs3212227 A IL12B T G 20.1525 0.0639 1.70E202 0.86 Opposite
Zhang et al. (74) rs3213094 ? IL12B T C 0.1565 0.0639 1.43E202 1.17
WTCCC2 (75) rs3213094 ?
Ellinghaus et al. (77) rs2546890 A IL12B A G 0.0075 0.0521 8.86E201 1.01
Hu ¨ffmeier et al. (78) rs12188300 T IL12B A T 0.2009 0.1092 6.57E202 1.22
Tsoi et al. (47) rs12188300
a T IL12B A T 0.2009 0.1092 6.57E202 1.22
Tsoi et al. (47) rs9504361 A EXOC2,IRF4 A G 0.0234 0.0526 6.56E201 1.02
Russell et al. (79) HLA-C
a0602
a0602 Others 20.2695 0.0946 4.40E203 0.76 Opposite
Tsoi et al. (47) rs4406273 A HLA-B,HLA-C C G 20.0251 0.1367 8.55E201 0.98
WTCCC2 (75) rs240993 A TRAF3IP2 T C 0.0586 0.0585 3.17E201 1.06
Hu ¨ffmeier et al. (78) rs13190932 A TRAF3IP2 A G 0.1121 0.1156 3.32E201 1.12
Tsoi et al. (47) rs33980500 T TRAF3IP2 A G 20.3152 0.1461 3.10E202 0.73 Opposite
Ellinghaus et al. (77) rs13210247 G TRAF3IP2 A G 20.1049 0.1086 3.34E201 0.90
Tsoi et al. (47) rs582757 C TNFAIP3 T C 20.1176 0.0574 4.05E202 0.89 Same
Nair et al. (73) rs610604 G TNFAIP3 T G 20.0889 0.0548 1.05E201 0.91
Tsoi et al. (47) rs2451258 C TAGAP T C 20.0813 0.0537 1.30E201 0.92
Tsoi et al. (47) rs2700987 A ELMO1 T C 0.0665 0.0538 2.17E201 1.07
Tsoi et al. (47) rs11795343 T DDX58 T C 0.0521 0.0521 3.17E201 1.05
Tsoi et al. (47) rs10979182 A KLF4 A G 20.0089 0.0541 8.69E201 0.99
Tsoi et al. (47) rs1250546 A ZMIZ1 A G 20.1066 0.0557 5.58E202 0.90
Tsoi et al. (47) rs645078 A RPS6KA4,PRDX5 A C 0.0045 0.0533 9.33E201 1.00
Tsoi et al. (47) rs4561177 A ZC3H12C A G 0.0652 0.0521 2.11E201 1.07
Tsoi et al. (47) rs3802826 A ETS1 A G 0.0849 0.0781 2.77E201 1.09
Nair et al. (73) rs2066808 A IL23A-STAT2 A G 0.1455 0.0950 1.26E201 1.16
Tsoi et al. (47) rs2066819 C STAT2,IL23A T C 20.1435 0.1008 1.54E201 0.87
Stuart et al. (80) rs12586317 T NFKBIA
WTCCC2 (75) rs8016947 C NFKBIA T G 0.0701 0.0511 1.70E201 1.07
Tsoi et al. (47) rs8016947 G NFKBIA T G 0.0701 0.0511 1.70E201 1.07
Tsoi et al. (47) rs367569 C PRM3,SOCS1 T C 20.1241 0.0584 3.35E202 0.88 Same
Stuart et al. (80) rs10782001 G FBXL19 A G 20.0311 0.0541 5.65E201 0.97
Tsoi et al. (47) rs12445568 C PRSS53,FBXL19 T C 20.0503 0.0533 3.46E201 0.95
Stuart et al. (80) rs4795067 G NOS2 A G 20.0063 0.0630 9.20E201 0.99
Tsoi et al. (47) rs28998802 A NOS2 C G 20.1283 0.1265 3.10E201 0.88
Tsoi et al. (47) rs963986
a C PTRF,STAT3,STAT5A/B C G 0.0829 0.0711 2.44E201 1.09
Tsoi et al. (47) rs11652075 C CARD14 T C 20.1287 0.0511 1.19E202 0.88 Same
Tsoi et al. (47) rs545979 T POL1,STARD6,MBD2 T C 20.1628 0.0576 4.75E203 0.85 Opposite
Tsoi et al. (47) rs34536443
a G TYK2 T C 0.0090 0.1030 9.30E201 1.01
WTCCC2 (75) rs12720356 A TYK2 A C 0.0341 0.0870 6.95E201 1.03
Tsoi et al. (47) rs892085 A ILF3,CARM1 A G 20.0083 0.0538 8.77E201 0.99
Capon et al. (81) rs495337 ? ZNF313 A G 20.0602 0.0521 2.47E201 0.94
Tsoi et al. (47) rs1056198 C RNF114 TC20.0576 0.0519 2.67E201 0.94
Tsoi et al. (47) rs4821124 C UBE2L3 TC20.0141 0.0662 8.32E201 0.99
Zhang study is for Asian samples (Chinese).
ars2233278 C/G rs12188300 A/T rs34536443 G/C rs963986 C/G.
4850 Human Molecular Genetics, 2013, Vol. 22, No. 23Europeanorigin,isdrivenbyindependenteffectsoftwoclassic-
al HLA alleles, HLA-DRB∗0701 and HLA-B∗4402.
The MHC complex exhibits high levels of population diver-
gence (50,51) reﬂecting, among other factors, local adaptation
toparasiteandpathogencommunities.Theregiondemonstrates
considerable geographical variation in LD (52) and allele fre-
quencies, as well as regional differences in the allelic spectrum
(53), implying the presence of distinct core haplotypes. It
remains unclear the extenttowhich the deviation inthepatterns
of association between Caucasian and Asian populations at this
locuscanbeattributedtodifferencesintheunderlyingLDstruc-
ture (and the same causal alleles) or separable, co-localized
population-speciﬁc effects.
PleiotropyisacommonfeatureemergingfromrecentGWAS.
Autoimmune diseases in particular have been mapped to many
shared loci with variable speciﬁcities for different diseases
(54). Attempts to model this phenomenon have indicated that
while the number of traits affected by any one gene is likely to
besmall,thosegenesassociatedwithhigherlevelsofpleiotropy
are likely to exert larger effects (55). As such, designation of
shared loci may represent a useful metric for the prioritization
of genes for further detailed mapping and functional analysis.
Here, by examination of the endophenotypes ‘AD and asthma’
and‘ADnoasthma’andbycomparisonofourresultswiththoseof
existing GWAS for other related phenotypes, we have found
that AD is determined by a combination of speciﬁc and shared
effects,withthec11orf30-LRRC2locusonchromosome11inpar-
ticular showing effects on AD, asthma and AR. Co-localization
between AD, asthma and rhinitis was largely mediated by the
same alleles, whereas in the sites of co-localization between AD
and psoriasis association was mediated by a combination of
sharedandopposingalleles,withthemostsigniﬁcanteffectsoper-
ating inopposingdirections. Thesedataareconsistentwithobser-
vationsofclinicalco-occurrencebetweenAD,rhinitisandasthma,
and relative clinical independence between AD and psoriasis.
While this study is well powered for the detection of small,
common effects underpinning the genetic origins of AD, it
suffersfromseverallimitations.Asthmastatuswasnotavailable
in all of our population-based cohorts, increasing the potential
for misclassiﬁcation bias. This may have resulted in a modest
loss ofstatistical power, giventhe prevalence ofthe phenotypes
studied. This effect has been mitigated through the use of
strict diagnostic criteria for cases status (see Materials and
Methods). Inclusion of cohorts from multiple geographic
origins may lead to unrecognized population heterogeneity
and false-positive errors. We have minimized this inﬂuence by
removal of non-European individuals; by principal components
analysis and inclusion of the top 10 components in the associ-
ation model and by separate analysis of the UK–Irish and
German portions of the cohort, followed by meta-analysis with
application of a genomic control estimate.
Untilrecently,thegeneticoriginsofADhavebeencharacter-
ized by a single robust major locus (FLG) and a multitude of
small,poorlyreplicatedeffects.OurlargeGWAShasconﬁrmed
anumberofknowneffectsanddemonstratedamarkedvariation
in the phenotypic contribution of particular loci. The data pre-
sented here thus support a complex model of AD that incorpo-
rates both epidermal barrier and immune mechanisms (56),
and a combination of shared and AD-speciﬁc effects.
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Human Molecular Genetics, 2013, Vol. 22, No. 23 4851Table 7. Association with published GWA markers for asthma
Reference SNP Risk
allele
Gene Allele
1
Allele
2
AD AD and asthma AD not asthma
Effect StdErr P OR Direction Effect StdErr P Effect StdErr P
Moffatt et al.( 67) rs7216389 T ORMDL3 T C 0.0882 0.0506 8.12E202 1.09 Same 0.2222 0.0701 1.53E203 ++ 0.0056 0.0617 9.28E201 2+
Himes et al.( 68) rs1588265 C PDE4D 22 22 22 22 22
Sleimanetal.(69) rs2786098 C DENND1B TG20.0912 0.063 1.48E201 0.91 Same 20.0116 0.0868 8.94E201 2+ 20.1543 0.0783 4.88E202 22
GABRIEL (36) rs3771166 A IL1RL1-IL18R1 AG20.1557 0.0539 3.88E203 0.86 Same 20.1148 0.0755 1.28E201 22 20.1783 0.0666 7.38E203 22
GABRIEL (36) rs9273349 C MHC 22 22 22 22 22
GABRIEL (36) rs1342326 C IL33 AC20.07 0.0677 3.02E201 0.93 Same 20.0783 0.0935 4.02E201 22 20.073 0.0831 3.79E201 22
GABRIEL (36) rs744910 A SMAD3 AG20.1045 0.0515 4.24E202 0.90 Same 20.1686 0.0709 1.75E202 22 20.0727 0.0627 2.46E201 22
GABRIEL (36) rs2305480 A GSDMB AG20.1441 0.0507 4.52E203 0.87 Same 20.2873 0.0714 5.79E205 20.0652 0.0617 2.91E201
GABRIEL (36) rs3894194 A GSDMA A G 0.1453 0.0513 4.64E203 1.16 Same 0.2761 0.0708 9.60E205 0.0596 0.0629 3.44E201
GABRIEL (36) rs2284033 A IL2RB AG20.0235 0.0519 6.51E201 0.98 Same 0.0715 0.072 3.21E201 ++ 20.0802 0.0641 2.11E201 22
Noguchi (70) rs3019885 G SLC30A8 TG20.1174 0.0524 2.51E202 0.89 Same 20.1354 0.072 6.01E202 2+ 20.1225 0.0653 6.08E202 22
Noguchi (70) rs987870 C HLA2DP AG20.0375 0.0744 6.14E201 0.96 Same 20.0676 0.1025 5.10E201 22 20.022 0.0915 8.10E201 +2
EVE (71) rs11078927 C GSDMB TC20.1436 0.0507 4.65E203 0.87 Same 20.2883 0.0714 5.44E205 22 20.0629 0.0617 3.08E201 22
EVE (71) rs1837253 C TSLP T C 0.0139 0.061 8.20E201 1.01 20.0746 0.086 3.86E201 22 0.0805 0.0747 2.81E201 ++
EVE (71) rs10173081 C IL1RL1 TC20.0723 0.075 3.35E201 0.93 20.0349 0.1038 7.37E201 +22 0.0942 0.0927 3.09E201 22
EVE (71) rs1101999 PYHIN1
Hirota et al.( 26) rs7686660 T FLJ44477 - USP38 T G 0.0451 0.0589 4.44E201 1.05 Same 0.1762 0.0839 3.57E202 ++ 20.036 0.0711 6.12E201 2+
Hirota et al.( 26) rs10508372 C KRT8P16 -
TCEB1P3
A G 0.0435 0.1058 6.81E201 1.04 Opposite 20.069 0.1488 6.43E201 22 0.1279 0.128 3.18E201 ++
Hirota et al.( 26) rs1701704 G SUOX - IKZF4 TG20.0979 0.0541 7.02E202 0.91 Same 20.1547 0.0746 3.81E202 22 20.0545 0.0666 4.13E201 22
Ferreira et al.( 72) rs4129267 T IL6R T C 0.122 0.0513 1.74E202 1.13 Same 0.1904 0.0713 7.56E203 ++ 0.078 0.0637 2.20E201 ++
Ferreira et al.( 72) rs7130588 G c11orf30-LRRC2 AG20.2619 0.0524 5.81E207 0.77 Same 20.2733 0.0727 1.71E204 22 20.2647 0.0644 3.94E205 22
NoguchiandHirotastudiesarefor Asian (Japanese)samples, andtheEVE signalforPYHIN1 wasdetectedonlyinindividualsof Africandescent.P-valuesbelowanominalthreshold of0.05 arehighlightedin
bold.
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3MATERIALS AND METHODS
Participants
The discovery dataset comprised 5617 individuals of European
ancestry, including 1563 AD cases, and 4054 population-based
controls. Individuals with AD were recruited from tertiary
dermatology clinics across three centres (Great Ormond Street
Hospital, London; Our Lady’s Children’s Hospital, Dublin;
and University Hospital rechts der Isar, Mu ¨nchen). The diagno-
sisofADwasmadebyexperienceddermatologistsorpaediatri-
cians according tothe UK diagnostic criteria (57).AllAD cases
had a reported disease onset in childhood and suffered from
moderate-to-severe disease at the time of recruitment. AD-free
controls were drawn from three population-based studies;
the cross-sectional International Study of Asthma and Allergies
in Childhood (ISAAC) Phase II (58), the Avon Longitudinal
Study of Children and Parents (ALSPAC) (59) and the 1958
Birth Cohort (60). Asthma status (deﬁned elsewhere (36))
was available for all datasets with the exception of the 1958
birth cohort. The 4,054 population controls were not selected
to be asthma-free, in order to allow unbiased analysis of the
three endophenotypes; AD, AD and asthma, AD no asthma.
The replication dataset comprised 5446 individuals of Euro-
peanAncestry,including2286ADcases,and3160AD-freecon-
trols. AD cases were dermatologist-diagnosed, recruited from
dermatology clinics at ﬁve sites across Germany, Ireland and
Sweden. Samples utilized in the replication phase were drawn
from the KORA S4/F4 population-based survey (61) ISAAC
Phase II, the Swedish longitudinal birth cohort BAMSE (62)
and a previously described set of unselected Irish population
controls derived from the Trinity College Dublin Biobank
(63). Controls of German and Swedish origin were both AD-
and asthma-free. Disease status was not available for the Irish
Biobank controls.
The study was approved by the institutional review boards at
eachoftheparticipatingstudysites.Awritteninformedconsent
for the collection and genotyping of DNA was obtained from
all study participants and/or their parents/guardians where
appropriate.
Genotyping
Genome-wide genotyping was performed on bar-coded LIMS
(Laboratory Information Management System) tracked
samples using the Illumina Sentrix HumanHap300 Genotyping
BeadChip (ALSPAC, UK families, German samples, ISAAC)
and the Illumina Human 610-Quad BeadChip (Irish samples,
1958BC) (Illumina, San Diego). BeadChips were processed
withinanautomatedBeadLabattheCentreNationaldeGenoty-
page as per the manufacturer’s instructions. Samples were
subject to strict quality control criteria including assessment
of concentration, fragmentation and response to PCR. A total
of 20 ml of DNA aliquoted to a concentration of 50 ng/ml was
used for each array. Replication phase genotyping was per-
formed using matrix-assisted laser desorption/ionization
time-of ﬂight (MALDI-TOF) mass spectrometry (http://www.
sequenom.com),orAppliedBiosystemsTaqManprobes(http://
www.appliedbiosystems.com/). Genotyping of Filaggrin var-
iants R501X, 2282del4, R2447X and S3247X was performed
as previously described (12,15,23). FLG genotype availability
anddistributionsaregiveninSupplementaryMaterial,TableS2.
Statistical analysis
In the discovery phase, genome-wide genotypes were used for
controlling the quality of the samples. First individuals with
call rates ,95% or sex inconsistencies were excluded. Next
principalcomponentsanalysisandidentity-by-descent(IBD)es-
timation were done using EIGENSOFT and PLINK version
1.07, respectively. Duplicates and individuals who were pos-
siblynon-Europeanwereremoved,andfromeachgroupofsub-
jects who exhibited a strong relationship only one subject was
randomlychosen(full-sibsorparent-offspring).Byusingthisﬁl-
tered sample set, we calculated quality control statistics, and
SNPs with call rates ,98% or SNPs with a Hardy–Weinberg
equilibrium test P–value ,1.0E206 were excluded. Finally,
268 034experimentallygenotypedSNPswithaminorallelefre-
quency .1%wereusedforimputationanalysis.Imputationwas
done using Mach and minimac software, following the instruc-
tions provided by the author (http://genome.sph.umich.edu/
wiki/Minimac). HapMap CEU release 22 reference panel was
used, and the imputed genetic dosage with R-squared statistics
.0.3 was used for the association analysis. As a result, 2543
887 SNPs were imputed, and association tests were performed
for 2406 139 SNPs with an imputation quality metric
R-squared value of .0.3 and a minor allele frequency of
.0.01. Association was tested separately in the UK–Irish and
German portions of the cohort using mach2dat software
(64,65), incorporating the top 10 principal components as
covariates. These data were then combined by ﬁxed-effects
meta-analysisaftergenomiccontrolwasappliedtobothdatasets.
Since null mutations in the FLG gene are known to be asso-
ciated with AD, we performed additional regression analysis
for all SNPs around the FLG gene conditioned on the two most
common FLG null alleles, R501X and 2282del4.
We also performed imputation of HLA alleles by using
HLA∗IMP software (29,30). To analyse imputed HLA alleles,
we treated post-probabilities as genetic dosages of the alleles
andestimatedtheireffectsintheregressionmodelinconjunction
with principal components as used in genome-wide analysis.
The frequencies of HLA alleles were calculated as the sum of
genetic dosage divided by the number of chromosomes. The lo-
gistic regression analysis was performed by R (release 2.13.0)
(66). In this analysis, signiﬁcance levels were Bonferroni-
corrected at each test group, i.e. nominal P-value of 5.0E202
divided by the number of tests carried out for one HLA locus.
From the results of association analysis, we chose SNPs which
showed P-values ,1.0E205 and evaluated these signals in
independent replication samples. SNPs in LD (r
2 . 0.3 in Hap-
Map_CEU) withanother markerwithalowerP-value, werenot
includedtoavoidredundancy.Asaresult,wechose47SNPsfor
thereplicationstage.Inaddition,SNPscategorizedascandidate
functional SNPs were selected from each LD bin. Association
was tested in the replication sets by meta-analysis using a
random-effects model as implemented in R (release 2.13.0). In
order to control for known AD susceptibility alleles located
within the EDC on chromosome 1, signiﬁcant markers were
included in a logistic regression incorporating the two most
common FLG null alleles.
Human Molecular Genetics, 2013, Vol. 22, No. 23 4853Genuine replication was considered if P-values exceeded
the threshold of 1.0E203 (0.05/47) and consistent effects in
the same direction were observed in the GWA as well as all
replication cohorts. Where markers implicated in psoriasis by
previous GWAS were not genotyped in our dataset, they were
imputed by mach1 phasing and minimac imputation using the
1000Gv3 template for EUR population as a reference panel,
and employing only those variants within 1 Mb of the target
SNP. All r
2 were .0.8, with the exception of rs4406273
which showed r
2 ¼ 0.67
eQTL
Genome-wide expression QTL (eQTL) data were available as
part of a prior study described in detail previously (27).
Brieﬂy, the eQTL data were generated from RNA extracted
from EBV-transformed lymphoblastoid cell lines originating
from 496 children within the UK portion of the discovery
cohort. Transcript abundance was measured on a genome-wide
scale using the Illumina Human 6 BeadChip and examined in
combination with the 1000 genomes imputed genotype data
described above to map genetic factors capable of moderating
expression.Non-geneticeffectswerecontrolledforusingaprin-
cipal components approach shown to increase power for the de-
tection of cis and trans-acting effects.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
ACKNOWLEDGEMENTS
We thank the Mutation Analysis Core Facility (MAF) at Karo-
linska Institutet for genotyping, and Lovisa Reinius and Inge-
gerd Fransson for technical assistance. We acknowledge the
use of genotype data from the British 1958 Birth Cohort DNA
collection, funded by the Medical Research Council and the
Wellcome Trust, and the ALSPAC Longitudinal Study of
Parents and Children.
Conﬂicts of Interest statement. None declared.
FUNDING
ThisworkwassupportedbytheWellcomeTrust(077326/Z/05/Z),
theMedicalResearchCouncil(G0700314),theFrenchMinistry
ofHigherEducationandResearch,theBritishSkinFoundation,
Ge ´nome Que ´bec, le Ministe `re de l’Enseignement supe ´rieur, de
la Recherche, de la Science et de la Technologie (MESRST)
Que ´bec and McGill University, the National Eczema Society,
the German Federal Ministry of Education and Research
(BMBF), the State of Bavaria and the German National
Genome Research Network (NGFN-2, NGFNPlus: 01GS0823,
01GS 0818) and donations from anonymous families affected
by eczema in the Tayside Region of Scotland. The BAMSE
study was supported by the Swedish Research Council,
Stockholm County Council, Centre for Allergy Research,
Karolinska Institutet and the Swedish Heart Lung Foundation.
S.W. is supported by a Heisenberg Professorship of the DFG
(grant WE 2678/7-1), the Christiane Ku ¨hne Centre for Allergy
ResearchandEducation(http://www.ck-care.ch/),theGraduate
School of Information Science in Health of the Technische
Universita ¨t Mu ¨nchen (TUM-GSISH), and S.W. and S.J.B. are
supported by the COST action ‘SkinBAD’. A.D.I., S.J.B. and
G.M.O.’R. are supported by the National Children’s Research
Centre, Dublin. A.D.I., S.J.B., G.M.O.’R., P.B. and W.H.I.M. are
supported by the Wellcome Trust (reference: 090066/B/09/Z,
092530/Z/10/Z). S.W.-O. is supported by the Freemasons
Grand Charity. S.J.B. holds a Wellcome Trust Fellowship (ref
086398/Z/08/Z). Funding to pay the Open Access publication
charges for this article was provided by the Wellcome Trust.
REFERENCES
1. Cookson,W.O.,Ubhi,B.,Lawrence,R.,Abecasis,G.R.,Walley,A.J.,Cox,
H.E.,Coleman,R.,Leaves,N.I.,Trembath,R.C.,Moffatt,M.F.etal.(2001)
Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility
loci. Nat. Genet., 27, 372–373.
2. Spergel,J.M.andPaller,A.S.(2003)Atopicdermatitisandtheatopicmarch.
J. Allergy Clin. Immunol., 112, S118–S127.
3. Lichtenstein, P. and Svartengren, M. (1997) Genes, environments, and sex:
factors of importance in atopic diseases in 7–9-year-old Swedish twins.
Allergy, 52, 1079–1086.
4. van Beijsterveldt, C.E. and Boomsma, D.I. (2007) Genetics of parentally
reported asthma, eczema and rhinitis in 5-yr-old twins. Eur. Respir. J., 29,
516–521.
5. Schultz Larsen, F. (1993) Atopic dermatitis: a genetic-epidemiologic study
in a population-based twin sample. J. Am. Acad. Dermatol., 28, 719–723.
6. Larsen, F.S., Holm, N.V. and Henningsen, K. (1986) Atopic dermatitis. A
genetic-epidemiologic study in a population-based twin sample. J. Am.
Acad. Dermatol., 15, 487–494.
7. Duffy, D.L., Martin, N.G., Battistutta, D., Hopper, J.L. and Mathews, J.D.
(1990) Genetics of asthma and hay fever in Australian twins. Am. Rev.
Respir. Dis., 142, 1351–1358.
8. Hopp,R.J.,Bewtra,A.K.,Watt,G.D.,Nair,N.M.andTownley,R.G.(1984)
Genetic analysis of allergic disease in twins. J. Allergy Clin. Immunol., 73,
265–270.
9. Nieminen,M.M.,Kaprio,J.andKoskenvuo,M.(1991)Apopulation-based
study of bronchial asthma in adult twin pairs. Chest, 100, 70–75.
10. Thomsen,S.F.,Ulrik,C.S.,Kyvik,K.O.,Hjelmborg,J.B.,Skadhauge,L.R.,
Steffensen, I. and Backer, V. (2007) Importance of genetic factors in the
etiology of atopic dermatitis: a twin study. Allergy Asthma Proc., 28,
535–539.
11. Palmer,C.N.,Irvine,A.D.,Terron-Kwiatkowski,A.,Zhao,Y.,Liao,H.,Lee,
S.P.,Goudie,D.R.,Sandilands,A.,Campbell,L.E.,Smith,F.J.etal.(2006)
Commonloss-of-functionvariantsoftheepidermalbarrierproteinﬁlaggrin
are a major predisposing factor for atopic dermatitis. Nat. Genet., 38,
441–446.
12. Smith, F.J., Irvine, A.D., Terron-Kwiatkowski, A., Sandilands, A.,
Campbell,L.E.,Zhao,Y.,Liao,H.,Evans,A.T.,Goudie,D.R.,Lewis-Jones,
S. et al. (2006) Loss-of-function mutations in the gene encoding ﬁlaggrin
cause ichthyosis vulgaris. Nat. Genet., 38, 337–342.
13. Irvine, A.D., McLean, W.H. and Leung, D.Y. (2011) Filaggrin mutations
associatedwithskinandallergicdiseases.N.Engl.J.Med.,365,1315–1327.
14. Rodriguez, E., Baurecht, H., Herberich, E., Wagenpfeil, S., Brown, S.J.,
Cordell, H.J., Irvine, A.D. and Weidinger, S. (2009) Meta-analysis of
ﬁlaggrinpolymorphismsineczemaandasthma:robustriskfactorsinatopic
disease. J. Allergy Clin. Immunol., 123, 1361–1370 e1367.
15. Morar, N., Cookson, W.O., Harper, J.I. and Moffatt, M.F. (2007) Filaggrin
mutationsinchildrenwithsevereatopicdermatitis.J.Invest.Dermatol.,127,
1667–1672.
16. Guttman-Yassky, E., Nograles, K.E. and Krueger, J.G. (2011) Contrasting
pathogenesisofatopicdermatitisandpsoriasis—partII:immunecellsubsets
and therapeutic concepts. J. Allergy Clin. Immunol., 127, 1420–1432.
17. Guttman-Yassky, E., Nograles, K.E. and Krueger, J.G. (2011) Contrasting
pathogenesis of atopic dermatitis and psoriasis–part I: clinical and
pathologic concepts. J. Allergy Clin. Immunol., 127, 1110–1118.
4854 Human Molecular Genetics, 2013, Vol. 22, No. 2318. Paternoster, L., Standl, M., Chen, C.M., Ramasamy, A., Bonnelykke, K.,
Duijts, L., Ferreira, M.A., Alves, A.C., Thyssen, J.P., Albrecht, E. et al.
(2012) Meta-analysis of genome-wide association studies identiﬁes three
new risk loci for atopic dermatitis. Nat. Genet., 44, 187–192.
19. Sun, L.D., Xiao, F.L., Li, Y., Zhou, W.M., Tang, H.Y., Tang, X.F., Zhang,
H., Schaarschmidt, H., Zuo, X.B., Foelster-Holst, R. et al. (2011)
Genome-wide association study identiﬁes two new susceptibility loci for
atopic dermatitis in the Chinese Han population. Nat. Genet., 43, 690–694.
20. Esparza-Gordillo, J., Weidinger, S., Folster-Holst, R., Bauerfeind, A.,
Ruschendorf,F.,Patone,G.,Rohde,K.,Marenholz,I.,Schulz,F.,Kerscher,
T.etal.(2009)Acommonvariantonchromosome11q13isassociatedwith
atopic dermatitis. Nat. Genet., 41, 596–601.
21. Hirota,T.,Takahashi,A.,Kubo,M.,Tsunoda,T.,Tomita,K.,Sakashita,M.,
Yamada, T., Fujieda, S., Tanaka, S., Doi, S. et al. (2012) Genome-wide
associationstudyidentiﬁeseightnewsusceptibilitylociforatopicdermatitis
in the Japanese population. Nat. Genet., 44, 1222–1226.
22. vandenOord,R.A.andSheikh,A.(2009)Filaggringenedefectsandriskof
developing allergic sensitisation and allergic disorders: systematic review
and meta-analysis. BMJ, 339, b2433.
23. Weidinger, S., O’Sullivan, M., Illig, T., Baurecht, H., Depner, M.,
Rodriguez, E., Ruether, A., Klopp, N., Vogelberg, C., Weiland, S.K. et al.
(2008) Filaggrin mutations, atopic eczema, hay fever, and asthma in
children. J. Allergy Clin. Immunol., 121, 1203–1209.
24. Irvine, A.D. (2007) Fleshing out ﬁlaggrin phenotypes. J. Invest. Dermatol.,
127, 504–507.
25. Kamatani, Y., Matsuda,K.,Ohishi, T.,Ohtsubo,S., Yamazaki, K.,Iida, A.,
Hosono,N.,Kubo,M.,Yumura,W.,Nitta,K.etal.(2008)Identiﬁcationofa
signiﬁcant association of a single nucleotide polymorphism in TNXB with
systemic lupuserythematosusina Japanesepopulation.J. Hum.Genet., 53,
64–73.
26. Hirota,T.,Takahashi,A.,Kubo,M.,Tsunoda,T.,Tomita,K.,Doi,S.,Fujita,
K., Miyatake, A., Enomoto, T., Miyagawa, T. et al. (2011) Genome-wide
association study identiﬁes three new susceptibility loci for adult asthma in
the Japanese population. Nat. Genet., 43, 893–896.
27. Liang, L., Morar, N., Dixon, A.L., Lathrop, G.M., Abecasis, G.R., Moffatt,
M.F. and Cookson, W.O. (2013) A cross-platform analysis of 14,177
expression quantitative trait loci derived from lymphoblastoid cell lines.
Genome Res., 23, 716–726.
28. Moutsianas, L., Enciso-Mora, V., Ma, Y.P., Leslie, S., Dilthey, A.,
Broderick,P.,Sherborne,A.,Cooke,R.,Ashworth,A.,Swerdlow,A.J.etal.
(2011)MultipleHodgkinlymphoma-associatedlociwithintheHLAregion
at chromosome 6p21.3. Blood, 118, 670–674.
29. Dilthey, A.T., Moutsianas, L., Leslie, S. and McVean, G. (2011)
HLA∗IMP—an integrated framework for imputing classical HLA alleles
from SNP genotypes. Bioinformatics, 27, 968–972.
30. Leslie, S., Donnelly, P. and McVean, G. (2008) A statistical method for
predicting classical HLA alleles from SNP data. Am. J. Hum. Genet., 82,
48–56.
31. Tekola Ayele, F., Adeyemo, A., Finan,C., Hailu, E., Sinnott, P., Burlinson,
N.D., Aseffa, A., Rotimi, C.N., Newport, M.J. and Davey, G. (2012) HLA
class II locus and susceptibility to podoconiosis. N. Engl. J. Med., 366,
1200–1208.
32. Schmitt-Egenolf, M., Boehncke, W.H., Stander, M., Eiermann, T.H. and
Sterry, W. (1993) Oligonucleotide typing reveals association of type I
psoriasis with the HLA-DRB1∗0701/2, -DQA1∗0201, -DQB1∗0303
extended haplotype. J. Invest. Dermatol., 100, 749–752.
33. Kastelan, M., Gruber, F., Cecuk-Jelicic, E., Grubic, Z. and Kastelan, A.
(2003) A new extended haplotype
Cw∗0602-B57-DRB1∗0701-DQA1∗0201-DQB1∗0201 associated with
psoriasis in the Croatian population. Clin. Exp. Dermatol., 28, 200–202.
34. Yang,S.,Ge,H.S.,Zhang,A.P.,Wei,S.C.,Gao,M.,Wang,H.Y.,Chen,J.J.,
Li,M.,Liang,Y.H.,He,P.P.etal.(2004)HaplotypeassociationsoftheMHC
withpsoriasisvulgarisinChineseHans.Clin.Exp.Dermatol.,29,399–405.
35. Buc, M., Fazekasova, H., Cechova, E., Hegyi, E., Kolibasova, K. and
Ferencik, S. (1998) Occurrence rates of HLA-DRB1, HLA-DQB1, and
HLA-DPB1 alleles in patients suffering from vitiligo. Eur. J. Dermatol., 8,
13–15.
36. Moffatt,M.F.,Gut,I.G.,Demenais,F.,Strachan,D.P.,Bouzigon,E.,Heath,
S., von Mutius, E., Farrall, M., Lathrop, M. and Cookson, W.O. (2010) A
large-scale, consortium-based genomewide association study of asthma.
N. Engl. J. Med., 363, 1211–1221.
37. Gudbjartsson,D.F.,Bjornsdottir,U.S.,Halapi,E.,Helgadottir,A.,Sulem,P.,
Jonsdottir, G.M., Thorleifsson, G., Helgadottir, H., Steinthorsdottir, V.,
Stefansson,H.etal.(2009)Sequencevariantsaffectingeosinophilnumbers
associatewithasthmaandmyocardialinfarction.Nat.Genet.,41,342–347.
38. Weidinger,S.,Gieger,C.,Rodriguez,E.,Baurecht,H.,Mempel,M.,Klopp,
N., Gohlke, H., Wagenpfeil, S., Ollert, M., Ring, J. et al. (2008)
Genome-wide scan on total serum IgE levels identiﬁes FCER1A as novel
susceptibility locus. PLoS Genet., 4, e1000166.
39. Vladich, F.D., Brazille, S.M., Stern, D., Peck, M.L., Ghittoni, R. and
Vercelli,D.(2005)IL-13R130Q,acommonvariantassociatedwithallergy
and asthma, enhances effector mechanisms essential for human allergic
inﬂammation. J. Clin. Invest., 115, 747–754.
40. Hindorff, L.A., MacArthur, J., Wise, A., Junkins,H.A., Hall, P.N., Klemm,
A.K.andManolio,T.A.,ACatalogofPublishedGenome-WideAssociation
Studies. http://www.genome.gov/gwastudies/.
41. Christophers, E. and Henseler, T. (1987) Contrasting disease patterns in
psoriasis and atopic dermatitis. Arch. Dermatol. Res., 279, S48–S51.
42. Szabo, S.J., Jacobson, N.G., Dighe, A.S., Gubler, U. and Murphy, K.M.
(1995) Developmental commitment to the Th2 lineage by extinction of
IL-12 signaling. Immunity, 2, 665–675.
43. Magram, J., Connaughton, S.E., Warrier, R.R., Carvajal, D.M., Wu, C.Y.,
Ferrante, J., Stewart, C., Sarmiento, U., Faherty, D.A. and Gately, M.K.
(1996)IL-12-deﬁcientmicearedefectiveinIFNgammaproductionandtype
1 cytokine responses. Immunity, 4, 471–481.
44. Mullen, A.C., High, F.A., Hutchins, A.S., Lee, H.W., Villarino, A.V.,
Livingston,D.M.,Kung,A.L.,Cereb,N.,Yao,T.P.,Yang,S.Y.etal.(2001)
RoleofT-betincommitmentofTH1cellsbeforeIL-12-dependentselection.
Science, 292, 1907–1910.
45. Cui,Q.,Zhang,Y.X.,Su,J.,Chen,X.,Ding,K.,Lei,N.,Liu,Y.,Li,J.,Zhang,
Y. and Yu, R.B. (2011) Genetic variation in IL28RA is associated with the
outcomesofHCVinfectioninahigh-riskChinesepopulation.Infect.Genet.
Evol., 11, 1682–1689.
46. Ryzhakov,G.,Blazek,K.,Lai,C.C.andUdalova,I.A.(2012)IL-17receptor
adaptor protein Act1/CIKS plays an evolutionarily conserved role in
antiviral signaling. J. Immunol., 189, 4852–4858.
47. Tsoi, L.C., Spain, S.L., Knight, J., Ellinghaus, E., Stuart, P.E., Capon, F.,
Ding,J.,Li,Y.,Tejasvi,T.,Gudjonsson,J.E.etal.(2012)Identiﬁcationof15
newpsoriasissusceptibilitylocihighlightstheroleofinnateimmunity.Nat.
Genet., 44, 1341–1348.
48. Jordan, C.T., Cao, L., Roberson, E.D., Duan, S., Helms, C.A., Nair, R.P.,
Dufﬁn, K.C., Stuart, P.E., Goldgar, D., Hayashi, G. et al. (2012) Rare and
common variants in CARD14, encoding an epidermal regulator of
NF-kappaB, in psoriasis. Am. J. Hum. Genet., 90, 796–808.
49. Ramasamy,A.,Curjuric,I.,Coin,L.J.,Kumar,A.,McArdle,W.L.,Imboden,
M., Leynaert, B., Kogevinas, M., Schmid-Grendelmeier, P., Pekkanen, J.
et al. (2011) A genome-wide meta-analysis of genetic variants associated
with allergic rhinitis and grass sensitization and their interaction with birth
order. J. Allergy Clin. Immunol., 128, 996–1005.
50. de Bakker, P.I., McVean, G., Sabeti, P.C., Miretti, M.M., Green, T.,
Marchini,J.,Ke,X.,Monsuur,A.J.,Whittaker,P.,Delgado,M.etal.(2006)
A high-resolution HLA and SNP haplotype map for disease association
studies in the extended human MHC. Nat. Genet., 38, 1166–1172.
51. Kitajima, H., Sonoda, M. and Yamamoto, K. (2012) HLA and SNP
haplotypemappingintheJapanesepopulation.GenesImmun.,13,543–548.
52. Teo,Y.Y.,Fry,A.E.,Bhattacharya,K.,Small,K.S.,Kwiatkowski,D.P.and
Clark, T.G. (2009) Genome-wide comparisons of variation in linkage
disequilibrium. Genome Res., 19, 1849–1860.
53. Suo, C., Xu, H., Khor, C.C., Ong, R.T., Sim, X., Chen, J., Tay, W.T., Sim,
K.S., Zeng, Y.X., Zhang, X. et al. (2012) Natural positive selection and
north–south genetic diversity in East Asia. Eur. J. Hum. Genet., 20,
102–110.
54. Ramos, P.S., Criswell, L.A., Moser, K.L., Comeau, M.E., Williams, A.H.,
Pajewski,N.M.,Chung,S.A.,Graham,R.R.,Zidovetzki,R.,Kelly,J.A.etal.
(2011) A comprehensive analysis of shared loci between systemic lupus
erythematosus (SLE) and sixteen autoimmune diseases reveals limited
genetic overlap. PLoS Genet., 7, e1002406.
55. Wang, Z., Liao, B.Y. and Zhang, J. (2010) Genomic patterns of pleiotropy
and the evolution of complexity. Proc. Natl. Acad. Sci. USA, 107, 18034–
18039.
56. Bieber, T. (2008) Atopic dermatitis. N. Engl. J. Med., 358, 1483–1494.
57. Williams,H.C.,Burney,P.G.,Pembroke,A.C.andHay,R.J.(1994)TheUK
Working Party’s diagnostic criteria for atopic dermatitis. III. Independent
hospital validation. Br. J. Dermatol., 131, 406–416.
58. Kabesch,M.,Carr,D.,Weiland,S.K.andvonMutius,E.(2004)Association
betweenpolymorphismsinserineproteaseinhibitor,kazaltype5andasthma
Human Molecular Genetics, 2013, Vol. 22, No. 23 4855phenotypes in a large German population sample. Clin. Exp. Allergy, 34,
340–345.
59. Golding, J. (1990) Children of the nineties. A longitudinal study of
pregnancyandchildhoodbasedonthepopulationofAvon(ALSPAC).West
Engl. Med. J., 105, 80–82.
60. Power, C. and Elliott, J. (2006) Cohort proﬁle: 1958 British birth cohort
(National Child Development Study). Int. J. Epidemiol., 35, 34–41.
61. Illig,T.,Gieger,C.,Zhai,G.,Romisch-Margl,W.,Wang-Sattler,R.,Prehn,
C.,Altmaier,E.,Kastenmuller,G.,Kato,B.S.,Mewes,H.W.etal.(2010)A
genome-wide perspective of genetic variation in human metabolism. Nat.
Genet., 42, 137–141.
62. Wickman,M.,Kull,I.,Pershagen,G.andNordvall,S.L.(2002)TheBAMSE
project: presentation of a prospective longitudinal birth cohort study.
Pediatr. Allergy Immunol., 13, 11–13.
63. O’Donovan, M.C., Craddock, N., Norton, N., Williams, H., Peirce, T.,
Moskvina, V., Nikolov, I., Hamshere, M., Carroll, L., Georgieva, L. et al.
(2008)Identiﬁcationoflociassociatedwithschizophreniabygenome-wide
association and follow-up. Nat. Genet., 40, 1053–1055.
64. Li, Y., Willer, C.J., Ding, J., Scheet, P. and Abecasis, G.R. (2010) MaCH:
using sequence and genotype data to estimate haplotypes and unobserved
genotypes. Genet. Epidemiol., 34, 816–834.
65. Li, Y., Willer, C., Sanna, S. and Abecasis, G. (2009) Genotype imputation.
Annu. Rev. Genomics Hum. Genet., 10, 387–406.
66. R Core Team (2013) R: A Language and Environment for Statistical
Computing, Vienna, http://www.R-project.org.
67. Moffatt,M.F.,Kabesch,M.,Liang,L.,Dixon,A.L.,Strachan,D.,Heath,S.,
Depner, M., von Berg, A., Bufe, A., Rietschel, E. et al. (2007) Genetic
variantsregulating ORMDL3expressioncontributetotheriskofchildhood
asthma. Nature, 448, 470–473.
68. Himes,B.E.,Hunninghake,G.M.,Baurley,J.W.,Rafaels,N.M.,Sleiman,P.,
Strachan,D.P.,Wilk,J.B.,Willis-Owen,S.A.,Klanderman,B.,Lasky-Su,J.
et al. (2009) Genome-wide association analysis identiﬁes PDE4D as an
asthma-susceptibility gene. Am. J. Hum. Genet., 84, 581–593.
69. Sleiman, P.M., Flory, J., Imielinski, M., Bradﬁeld, J.P., Annaiah, K.,
Willis-Owen, S.A., Wang, K., Rafaels, N.M., Michel, S., Bonnelykke, K.
et al. (2010) Variants of DENND1B associated with asthma in children.
N. Engl. J. Med., 362, 36–44.
70. Noguchi,E.,Sakamoto,H.,Hirota,T.,Ochiai,K.,Imoto,Y.,Sakashita,M.,
Kurosaka, F., Akasawa, A., Yoshihara, S., Kanno, N. et al. (2011)
Genome-wide association study identiﬁes HLA-DP as a susceptibilitygene
for pediatric asthma in Asian populations. PLoS Genet., 7, e1002170.
71. Torgerson, D.G., Ampleford, E.J., Chiu, G.Y., Gauderman, W.J., Gignoux,
C.R.,Graves,P.E.,Himes,B.E.,Levin,A.M.,Mathias,R.A.,Hancock,D.B.
etal.(2011)Meta-analysisofgenome-wideassociationstudiesofasthmain
ethnically diverse North American populations. Nat. Genet., 43, 887–892.
72. Ferreira,M.A.,Matheson,M.C.,Duffy,D.L.,Marks,G.B.,Hui,J.,LeSouef,
P.,Danoy,P.,Baltic,S.,Nyholt,D.R.,Jenkins,M.etal.(2011)Identiﬁcation
of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet, 378,
1006–1014.
73. Nair, R.P., Dufﬁn, K.C., Helms, C., Ding, J., Stuart, P.E., Goldgar, D.,
Gudjonsson, J.E., Li, Y., Tejasvi, T., Feng, B.J. et al. (2009) Genome-wide
scan reveals association of psoriasis with IL-23 and NF-kappaB pathways.
Nat. Genet., 41, 199–204.
74. Zhang,X.J.,Huang,W.,Yang,S.,Sun,L.D.,Zhang,F.Y.,Zhu,Q.X.,Zhang,
F.R., Zhang, C., Du, W.H., Pu, X.M. et al. (2009) Psoriasis genome-wide
associationstudyidentiﬁessusceptibilityvariantswithinLCEgeneclusterat
1q21. Nat. Genet., 41, 205–210.
75. Strange,A.,Capon,F.,Spencer,C.C.,Knight,J.,Weale,M.E.,Allen,M.H.,
Barton, A., Band, G., Bellenguez, C., Bergboer, J.G. et al. (2010) A
genome-wide association study identiﬁes new psoriasis susceptibility
loci and an interaction between HLA-C and ERAP1. Nat. Genet., 42,
985–990.
76. Cargill,M.,Schrodi,S.J.,Chang,M.,Garcia,V.E.,Brandon,R.,Callis,K.P.,
Matsunami, N., Ardlie, K.G., Civello, D., Catanese, J.J. et al. (2007) A
large-scale genetic association study conﬁrms IL12B and leads to the
identiﬁcation of IL23R as psoriasis-risk genes. Am. J. Hum. Genet., 80,
273–290.
77. Ellinghaus, E., Ellinghaus, D., Stuart, P.E., Nair, R.P., Debrus, S., Raelson,
J.V., Belouchi, M., Fournier, H., Reinhard, C., Ding, J. et al. (2010)
Genome-wide association study identiﬁes a psoriasis susceptibility locus at
TRAF3IP2. Nat. Genet., 42, 991–995.
78. Huffmeier,U.,Uebe,S.,Ekici,A.B.,Bowes,J.,Giardina,E.,Korendowych,
E., Juneblad, K., Apel, M., McManus, R., Ho, P. et al. (2010) Common
variantsatTRAF3IP2areassociatedwithsusceptibilitytopsoriaticarthritis
and psoriasis. Nat. Genet., 42, 996–999.
79. Russell, T.J., Schultes, L.M. and Kuban, D.J. (1972) Histocompatibility
(HL-A)antigensassociatedwith psoriasis.N. Engl. J. Med., 287, 738–740.
80. Stuart, P.E., Nair, R.P., Ellinghaus, E., Ding, J., Tejasvi, T., Gudjonsson,
J.E., Li, Y., Weidinger, S., Eberlein, B., Gieger, C. et al. (2010)
Genome-wide association analysis identiﬁes three psoriasis susceptibility
loci. Nat. Genet., 42, 1000–1004.
81. Capon, F., Bijlmakers, M.J., Wolf, N., Quaranta, M., Huffmeier, U., Allen,
M.,Timms,K.,Abkevich,V.,Gutin,A.,Smith,R.etal.(2008)Identiﬁcation
of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum. Mol.
Genet., 17, 1938–1945.
4856 Human Molecular Genetics, 2013, Vol. 22, No. 23